拉米夫定治疗乙型肝炎肝硬化患者的临床疗效分析

The Analysis of Clinical Effect on Lamivudine in the Treatment of Hepatitis B Cirrhosis

目的:评价拉米夫定对乙型肝炎肝硬化患者的临床疗效。方法:将107例乙型肝炎肝硬化患者随机分为对照组(55例)和治疗组(52例)。对照组给予常规保肝治疗,治疗组在常规治疗基础上加用拉米夫定(100mg/d),疗程1年。比较、观察两组患者肝功能、Child-Pugh评分、HBV DNA阴转率、肝纤维化指标(HA、LN、PⅢP、Ⅳ-C)的变化。结果:对照组、治疗组总有效率分别为61.8%、86.5%,两者之间有统计学差异(P<0.01)。治疗组患者治疗1年后肝功能、肝纤维化指标、Child-Pugh评分及HBV DNA阴转率均较对照组显著改善(P<0.05)。结论:拉米夫定可抑制HBVDNA的复制,有效提高丙氨酸氨基转移酶的复常率,改善肝功能。

Objective：To analysize the clinical effect of lamivudine on hepatitis B cirrhosis patients.Methods：107 patients with hepatitis B cirrhosis were randomly divided into control group（55 patients） and treatment group（52 patients）.The control group received traditional liver-protecting therapy alone,while the treatment group received additional lamivudine（100 mg/d,1 year）.The liver function,Child-Pugh grade,HBV DNA and liver fibrosis markers （HA,LN,PⅢP and Ⅳ-C） were observed.Results：The total effective rate in treatment group（86.5%） was higher than that in control group（61.8%）（P0.01）.There were significant differences of liver fibrosis markers（HA,LN,PⅢP and Ⅳ-C）,liver function,Child-Pugh grade and HBV DNA between treatment group and control group after treatment（P0.05）.Conclusion：Lamivudine controls the copy of HBV DNA,improves liver function effectively and finally achieves the treatment goal against liver cirrhosis.